Experimental and Molecular Therapeutics

Abstract 1893: Activating NRAS mutations are associated with FLT3-independent resistance to the clinically active FLT3 inhibitor AC220 in vitro.

Experimental and Molecular Therapeutics

Elisabeth A. Lasater, Catherine C. Smith, Neil P. Shah

Abstract 4737: Saturation mutagenesis of FLT3-ITD: AC220-resistance-conferring kinase domain mutations are restricted to a limited number of residues and are cross-resistant to sorafenib in vitro.

Experimental and Molecular Therapeutics

Catherine C. Smith, Lauren Damon, Sara Salerno, Neil P. Shah